UNICREDIT BANK/CALL/VERTEX PHARMACEUTICALS/400/0.1/19.06.24 | Market Closed - BOERSE MUENCHEN 15:42:14 2024-06-14 EDT | ||
| 7.6 EUR | +3.97% |
|
| Current month | +47.00% | ||
| 1 month | +158.50% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-06-14 | 7.6 | +3.97% |
| 24-06-13 | 7.31 | +4.58% |
| 24-06-12 | 6.99 | -8.87% |
| 24-06-11 | 7.67 | -2.29% |
| 24-06-10 | 7.85 | -0.13% |
Real-time BOERSE MUENCHEN
Last update June 14, 2024 at 03:42 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
UniCredit
|
| WKN | HC49PR |
| ISIN | DE000HC49PR5 |
| Date issued | 2023-02-20 |
| Strike | 400 $ |
| Maturity | 2024-06-19 (3 Days) |
| Parity | 10 : 1 |
| Emission price | 1.72 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 7.88 € |
|---|---|
| Lowest since issue | 1.36 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
480.7
USD
Average target price
463.4
USD
Spread / Average Target
-3.60%
- Stock Market
- Warrants
- Warrant
